Metabolic - 500 Beiträge pro Seite
eröffnet am 17.07.00 14:36:45 von
neuester Beitrag 15.05.03 17:38:27 von
neuester Beitrag 15.05.03 17:38:27 von
Beiträge: 15
ID: 187.473
ID: 187.473
Aufrufe heute: 0
Gesamt: 698
Gesamt: 698
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
vor 10 Minuten | 7113 | |
vor 17 Minuten | 4316 | |
vor 23 Minuten | 2460 | |
vor 35 Minuten | 2458 | |
heute 09:10 | 2089 | |
vor 26 Minuten | 1940 | |
heute 12:24 | 1807 | |
vor 14 Minuten | 1513 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 17.895,35 | -1,07 | 223 | |||
2. | 3. | 150,90 | -0,44 | 99 | |||
3. | 2. | 9,4450 | -2,07 | 91 | |||
4. | 4. | 0,1885 | -2,84 | 80 | |||
5. | 6. | 0,0211 | -32,59 | 53 | |||
6. | 34. | 0,6300 | -55,00 | 47 | |||
7. | 13. | 389,70 | -15,57 | 45 | |||
8. | 5. | 6,7540 | +0,15 | 42 |
Hallo,
Metabolic sind eine Australische Gentechnik Firma mit zwei Produkten in der klinischen Erprobung gegen Diabetes und Fettleibigkeit ( häufigste Todesursachen nach Schlaganfall) und seit Juni im deutschen Freiverkehr in Berlin gehandelt.
Tests bisher sehr positiv und anscheinend keine Geldprobleme. Website www.metabolic.com.au
Metabolic sind eine Australische Gentechnik Firma mit zwei Produkten in der klinischen Erprobung gegen Diabetes und Fettleibigkeit ( häufigste Todesursachen nach Schlaganfall) und seit Juni im deutschen Freiverkehr in Berlin gehandelt.
Tests bisher sehr positiv und anscheinend keine Geldprobleme. Website www.metabolic.com.au
Wo kann ich denn den Kurs in Australien abfragen?????
Danke
Danke
Metabolic 924219 - Anschauen. www.metabolic.com
Schaut Euch mal den Chart an
WKN924219 Metabolic
WKN924219 Metabolic
Das Kürzel ist MBP. Kursinformationen finden sich auf verschiedenen australischen Finanzseiten;
Übersicht: http://www.australia-pool.com/
.
Übersicht: http://www.australia-pool.com/
.
WEnn wenig Umsatz dann kommt so was raus
Aktueller Kurs 0,44 G
Kurszeit 26.03., 19:48
Differenz +0,395 (+877,78%)
Denn heimischen kurs gibts unter :
www.asx.com.au
Aktueller Kurs 0,44 G
Kurszeit 26.03., 19:48
Differenz +0,395 (+877,78%)
Denn heimischen kurs gibts unter :
www.asx.com.au
HOMEX - Melbourne
+++++++++++++++++++++++++
The loss of the Company for the half year ended 31 December 2002
after provision for income tax of nil was $3,284,751 (2001:
$1,804,805). The loss for the period includes fully expensing the sum
of $3,107,745 in respect of Research and Development costs. The
majority of this expenditure was incurred on furthering the exciting
progress already made on the Company`s main project, obesity drug
AOD9604. Income for the period totalled $270,582 representing
interest received.
In early February 2002 Metabolic announced results from a single dose
intravenous Phase 2A human clinical safety trial indicating signs of
drug activity and clear indications of weight loss. A subsequent
clinical trial to assess safety was conducted by oral dosing, results
of which were reported in August 2002 and this trial confirmed
bioactivity of AOD9604 via oral administration.
Metabolic`s most recent trial was a Phase 2A multiple oral dose
safety trial involving 36 patients, treated daily for one week.
Dosing was completed in December 2002 and on 3 March 2003 the results
of this trial were announced indicating further evidence of the
safety and tolerability of AOD9604 together with clear trends in body
weight reduction.
A feasibility study with BresaGen Ltd was also initiated during the
period to develop a scaleable method of manufacture of AOD9604 using
bacterial fermentation. In addition, supporting activities including
long term animal toxicity studies on AOD9604 were commenced.
Programs of preclinical evaluation continued on the Company`s early
stage research compounds, in the fields of diabetes, osteoporosis and
iron overload. Progress is expected to be reported in our next
Investor Update which we anticipate will be provided in April 2003.
D Kenley
COMPANY SECRETARY
MORE TO FOLLOW
+++++++++++++++++++++++++
The loss of the Company for the half year ended 31 December 2002
after provision for income tax of nil was $3,284,751 (2001:
$1,804,805). The loss for the period includes fully expensing the sum
of $3,107,745 in respect of Research and Development costs. The
majority of this expenditure was incurred on furthering the exciting
progress already made on the Company`s main project, obesity drug
AOD9604. Income for the period totalled $270,582 representing
interest received.
In early February 2002 Metabolic announced results from a single dose
intravenous Phase 2A human clinical safety trial indicating signs of
drug activity and clear indications of weight loss. A subsequent
clinical trial to assess safety was conducted by oral dosing, results
of which were reported in August 2002 and this trial confirmed
bioactivity of AOD9604 via oral administration.
Metabolic`s most recent trial was a Phase 2A multiple oral dose
safety trial involving 36 patients, treated daily for one week.
Dosing was completed in December 2002 and on 3 March 2003 the results
of this trial were announced indicating further evidence of the
safety and tolerability of AOD9604 together with clear trends in body
weight reduction.
A feasibility study with BresaGen Ltd was also initiated during the
period to develop a scaleable method of manufacture of AOD9604 using
bacterial fermentation. In addition, supporting activities including
long term animal toxicity studies on AOD9604 were commenced.
Programs of preclinical evaluation continued on the Company`s early
stage research compounds, in the fields of diabetes, osteoporosis and
iron overload. Progress is expected to be reported in our next
Investor Update which we anticipate will be provided in April 2003.
D Kenley
COMPANY SECRETARY
MORE TO FOLLOW
Metabolic (ASX code: MBP) has the mission of developing therapies for Metabolic diseases with application to worldwide markets , including obesity, obesity-related diseases such as type 2 diabetes, and more recently, iron-overload diseases.
The company`s operating strategy is to adopt where possible a "virtual" structure, minimising infrastructure and overhead costs while maximising access to world-class expertise. Contract research organisations and other contract developers are being used for all aspects of the companies pharmaceutical developments, including formulation, manufacturing, preclinical studies and clinical studies. Metabolic Pharmaceuticals has now established modern laboratories at the Baker Medical Research Institute (Melbourne) and the Heart Research Institute (Sydney). Expert consultants are used as appropriate to assist in the design and review of all aspects of the company`s activities.
These outsourcing activities are closely controlled by the company`s management, which has the benefit of substantial skills and experience in the clinical development of drugs, the management of research and high-level decision-making in international pharmaceutical industry.
Please follow the links below for details on the company`s major projects:
AOD9604 - OBESITY
Veterinary fat reducing product
ADD - DIABETES
MBP0201 - IRON OVERLOAD
MBP0250/0260 - OSTEOPOROSIS
The company`s operating strategy is to adopt where possible a "virtual" structure, minimising infrastructure and overhead costs while maximising access to world-class expertise. Contract research organisations and other contract developers are being used for all aspects of the companies pharmaceutical developments, including formulation, manufacturing, preclinical studies and clinical studies. Metabolic Pharmaceuticals has now established modern laboratories at the Baker Medical Research Institute (Melbourne) and the Heart Research Institute (Sydney). Expert consultants are used as appropriate to assist in the design and review of all aspects of the company`s activities.
These outsourcing activities are closely controlled by the company`s management, which has the benefit of substantial skills and experience in the clinical development of drugs, the management of research and high-level decision-making in international pharmaceutical industry.
Please follow the links below for details on the company`s major projects:
AOD9604 - OBESITY
Veterinary fat reducing product
ADD - DIABETES
MBP0201 - IRON OVERLOAD
MBP0250/0260 - OSTEOPOROSIS
der Chart sieht zur Zeit nicht gerade vielversprechend aus:
Aktienfossil
Aktienfossil
könnte ein Rohrkrepierer sein. Andererseits könnte der Kurs aus charttechnischer Sicht auch wieder nach oben drehen, wenn die 0,61 $ halten. In dem Fall könnte sich hochspekulativ ausgerichteten Investoren die Möglichkeit eines Einstiegs zu Tiefstkursen bieten. Aber nur wenn die Strategie aufgeht, bei MBP bin ich eher skeptisch
ozfreak
ozfreak
dreht MBP gerade wieder nach Norden ab?
Aktienfossil
Aktienfossil
sieht fast so aus als hätte sich Metabolic noch einmal gefangen. Jetzt müssen erst mal die 0,7 $ wieder in Angriff genommen werden und das dürfte nicht leicht sein.
ozfreak
ozfreak
heute wieder ein kleines Plus von 1 Cent. Mühsam ernährt sich das Eichhörnchen....
Aktienfossil
Aktienfossil
sieht ganz so aus als ob die 0,6 noch mal getestet werden. Ich bezweifle ja dass die Aktie ein 3. Mal abprallt. Raus und erst mal Finger weg würde ich sagen.
sind ja mehr oder weniger heftige Kursausschläge. Sollte es noch mal runter auf 0,5 gehen, überlege ich mir ein bisschen Taschengeld zu setzen.
TS
TS
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
223 | ||
99 | ||
91 | ||
80 | ||
53 | ||
47 | ||
45 | ||
42 | ||
41 | ||
32 |
Wertpapier | Beiträge | |
---|---|---|
30 | ||
28 | ||
27 | ||
26 | ||
26 | ||
24 | ||
23 | ||
21 | ||
20 | ||
19 |